Poll: 47% of Americans Hesitant to Get Covid-19 Vaccine
Many Americans are hesitant to be vaccinated against Covid-19, according to research from Invisibly.
If you are not happy with the results below please do another search
Many Americans are hesitant to be vaccinated against Covid-19, according to research from Invisibly.
Severe allergic reactions to Moderna Inc.’s coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said, after more than 4 million people received their first dose.
With the Pfizer-BioNTech and Moderna Covid-19 vaccines authorized in the United States and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for the company’s one-shot vaccine in hopes to help mitigate some of the country’s distribution problems.
GlaxoSmithKline discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Australia-based Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
Walmart Inc. is preparing to offer Covid-19 vaccinations in seven more states, as well as in Chicago and Puerto Rico, expanding beyond the two states where the company’s pharmacists are offering inoculations.
W2O announced the creation of three new positions to lead the global health innovation leader’s continued growth and transformation across the healthcare spectrum.
U.S. public health officials said a second Covid-19 shot could be administered as much as six weeks apart from the first one in situations where it was not possible to get a booster dose immediately.
Reuters found new evidence that the U.S. Centers for Disease Control and Prevention’s (CDC) response to the pandemic was marred by actions – or inaction – by the agency’s career scientists and frontline staff.
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents in a Phase III trial.
The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.